Targeting Triple-negative Breast Cancer
The FDA has approved a type of molecularly targeted therapeutic called an antibody-drug conjugate for the treatment of metastatic...
Progress Against Cancer
The FDA has approved a type of molecularly targeted therapeutic called an antibody-drug conjugate for the treatment of metastatic...
The FDA has approved a new molecularly targeted therapeutic for treating certain patients with advanced or metastatic HER2-positive breast...
A new study suggests that a HER2-targeted therapy approved for breast cancer may be effective for several other cancers....
A new study finds that Latina women with a higher proportion of Indigenous American ancestry may be at increased...
The FDA has expanded the use of the molecularly targeted therapeutic neratinib to include the treatment of certain patients...
The FDA approved a new treatment for adults with advanced breast cancer that has developed resistance to other targeted...
While most primary cancer diagnoses have no standard of care for brain metastasis screening, a study published in Cancer...
A study found that African American and Hispanic women in Chicago were exposed to higher levels of ambient toxic...
The molecularly targeted therapeutic alpelisib was approved for certain patients who have advanced or metastatic breast cancer. The U.S....
The FDA approval is for the use of atezolizumab in combination with Abraxane for the treatment of certain patients...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 47,000 members worldwide drive progress against cancer.
Donate Today